Therapy in hidradenitis suppurativa

There is currently an unmet need for new treatments for hidradenitis suppurativa (HS)

The authors of this prospective, randomised, double-blind, placebo-controlled study in Denmark investigated the efficacy of adalimumab in the treatment of HS. Twenty-one patients were randomised two to one to active treatment with adalimumab 80mg subcutaneously at baseline followed by 40mg subcutaneously every other week for 12 weeks (n = 15) or placebo (n = 6).

After six weeks, a significant reduction in severity of HS was seen and after 12 weeks, the reduction was almost significant. Adalimumab therefore reduces the severity of HS and improves quality of life in patients with this chronic inflammatory disease, the researchers say.
Miller I, Lynggaard CD, Lophaven S et al. Br J Dermatol 2011; 165: 391-8

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more